肿瘤细胞治疗研究
英文原题：Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults.
尽管儿童、青少年和年轻成人（CAYAs）成熟 B 细胞非霍奇金淋巴瘤（B-NHL）经化学免疫治疗的治愈率极佳，但复发/难治性 B-NHL 的 CAYAs 仍难以治疗，预后极差。
尽管化学免疫疗法治疗成熟 B 细胞非霍奇金淋巴瘤（B-NHL）儿童、青少年和青年（CAYA）患者的治愈率很高，但复发/难治性 B-NHL CAYA 患者仍难以治疗，预后极差。再诱导及后续治疗管理尚无标准方案。针对 B-NHL 的有效药物库持续扩充，包括抗体药物偶联物、单克隆抗体、检查点抑制剂、T 细胞衔接剂、CAR T 细胞、CAR 自然杀伤（CAR-NK）细胞和细胞信号抑制剂。本文回顾这一难治人群的当前管理实践及新型疗法。
Despite excellent cure rates among children, adolescents, and young adults (CAYAs) with mature B-cell non-Hodgkin lymphomas (B-NHLs) treated with chemoimmunotherapy, CAYAs with relapsed/refractory B-NHL remain difficult to treat, with a dismal prognosis. Reinduction and subsequent therapeutic management are not standardized. The armamentarium of active agents against B-NHL, including antibody-drug conjugates, monoclonal antibodies, checkpoint inhibitors, T-cell engagers, CAR T cells, CAR-natural killer (CAR-NK) cells, and cell signaling inhibitors, continues to expand. This article reviews current management practices and novel therapies in this difficult to treat population.
MEMBER ACCOUNT
登录成功会直接打开下一页。
